- Home
- WHF vs TARA Comparison
WHF vs TARA Comparison
Compare WHF & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WHF | TARA |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.5M | 165.5M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | WHF | TARA |
|---|---|---|
| Price | $6.95 | $5.01 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $7.75 | ★ $21.00 |
| AVG Volume (30 Days) | 181.8K | ★ 899.2K |
| Earning Date | 03-06-2026 | 03-04-2026 |
| Dividend Yield | ★ 14.96% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $76,339,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.31 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.39 | $2.77 |
| 52 Week High | $11.31 | $7.82 |
Technical Indicators
Market Signals| Indicator | WHF | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 46.31 | 42.01 |
| Support Level | $6.81 | $4.80 |
| Resistance Level | $7.09 | $5.14 |
| Average True Range (ATR) | 0.16 | 0.35 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 38.10 | 24.61 |
Price Performance
Historical ComparisonAbout WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).